Oklahoma Center for the Advancement of Science and Technology; requiring certain commitments before awarding certain contracts for health research projects; providing for exception. Effective date.
Impact
The legislation is expected to solidify the Oklahoma Center for the Advancement of Science and Technology's role in overseeing health research funding. By mandating that institutions involved in research are primarily located in Oklahoma and have financial responsibilities for the contracts awarded, the bill aims to improve local involvement in health research initiatives and promote economic growth. Additionally, the bill prohibits the use of funds for patient care unless it is an essential aspect of the funded projects, redirecting the focus towards research outputs.
Summary
SB214 aims to amend existing Oklahoma laws regarding health research funding by introducing stricter criteria for awarding professional service contracts. This bill necessitates that funds for health research projects are not only based on scientific merit but also require specific binding commitments from receiving institutions to report on various performance metrics for a period of six years. This change seeks to enhance accountability and ensure that funded projects yield measurable economic and employment impacts.
Sentiment
The sentiment surrounding SB214 appears to be generally positive among lawmakers who value accountability and local economic development. Proponents of the bill view it as a necessary update to ensure that health research funding benefits state residents and aligns with scientific standards. However, there may be concerns among some stakeholders regarding the limitations imposed on how funds can be utilized, particularly regarding patient care.
Contention
Notable points of contention may arise from the bill's requirements for detailed reporting and binding commitments from institutions. Some critics could argue that these requirements could deter participation from smaller organizations that may find the reporting burdensome. Additionally, the prohibition of using funds for direct patient care could be contentious, as it might limit the applicability of some research initiatives that inherently involve patient treatment or care as part of their projects.
Oklahoma Center for the Advancement of Science and Technology; requiring certain commitments before awarding certain contracts for health research projects; providing for exception. Effective date.
State government; creating the Oklahoma Center for the Advancement of Science and Technology Program Modernization Act; modifying powers and duties; effective date.
State government; creating the Oklahoma Center for the Advancement of Science and Technology Program Modernization Act; modifying powers and duties; effective date.
Economic development; creating the Research and Development Attraction Act; Oklahoma Center for the Advancement of Science and Technology; funds; effective date.
Economic development; creating the Center for the Advancement of Science and Technology Intern Partnership STEM Workforce Pipeline Program; effective date; emergency.
Oklahoma Center for the Advancement of Science and Technology; making appropriations; source; amount; purpose; compliance; reports; requiring appearance before certain joint committee; emergency.
Oklahoma Center for the Advancement of Science and Technology; purpose; expenditure limitations and procedures; lapse date; prohibiting certain budget procedures.
Oklahoma Center for the Advancement of Science and Technology; requiring certain commitments before awarding certain contracts for health research projects; providing for exception. Effective date.
Mandates insurance policies, provides coverage to diagnose & treat infertility for women between 25 & 42 years, including pre-implantation genetic diagnosis (PGD) in conjunction with in vitro fertilization (IVF).
Mandates all insurance contracts, plans or policies provide insurance coverage for the expense of testing and treating infertility, including preimplantation genetic testing (PGT), in conjunction with in vitro fertilization (IVF).
Mandates all insurance contracts, plans or policies provide insurance coverage for the expense of diagnosing and treating infertility, for women between the ages of 25 and 42 years including preimplantation genetic diagnosis (PGD) in conjunction with IVF.
Mandates insurance policies, provides coverage to diagnose & treat infertility for women between 25 & 42 years, including pre-implantation genetic diagnosis (PGD) in conjunction with in vitro fertilization (IVF).